GABAergic and serotonergic systems constitute the two principal targets of anxiolytic pharmacology, yet several neuropeptides, Selank, Semax, and DSIP (delta sleep-inducing peptide), engage these systems through indirect mechanisms that produce anxiolytic-like profiles in preclinical models without the sedation, tolerance, or dependence liabilities associated with direct GABA-A agonism. This article examines the mechanistic evidence in preclinical anxiety models, with focus on receptor-level interactions and validated behavioral endpoints.
Selank and GABAergic tone
Selank's anxiolytic mechanism involves indirect GABAergic potentiation through enkephalin-degrading enzyme inhibition. Critically, Selank's anxiolytic effect is not blocked by flumazenil (benzodiazepine site antagonist), confirming non-BZ site mechanism, but is partially attenuated by bicuculline (GABA-A competitive antagonist at GABA binding site), suggesting ultimate GABAergic mediation.
Semax and 5-HT turnover
Semax's cognitive effects are accompanied by serotonergic modulation: acute intranasal administration in rats increases frontal cortex 5-HT turnover (5-HIAA/5-HT ratio, measured by HPLC with electrochemical detection) by approximately 25–35%. The anxiolytic-relevant implication is that 5-HT1A activation (partial agonist action downstream of increased 5-HT synthesis/release) is associated with anxiolysis in multiple models. Semax does not directly bind 5-HT1A in radioligand assays, suggesting the serotonergic effect is secondary to upstream peptidergic modulation of 5-HT neuron excitability, potentially via BDNF/TrkB-mediated survival and dendritic remodeling of raphe serotonin neurons, which express TrkB at high density.
DSIP at the sleep and anxiety interface
DSIP (delta sleep-inducing peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is an endogenous nonapeptide originally isolated from rabbit thalamic venous blood during slow-wave sleep induction. DSIP also modulates NMDAR (N-methyl-D-aspartate receptor) activity in hippocampal slice preparations, reducing NMDA-evoked depolarization amplitude by approximately 20% at 100 nM, a potential secondary anxiolytic mechanism via reduction of excitatory drive on anxiety circuitry.
Assays used in anxiety models
- Primary anxiety assays: EPM (open arm time, %; control for locomotion separately), Vogel Conflict Test (punished licks), Open Field (center/periphery ratio, thigmotaxis), SIH (ΔT rectal temperature)
- Key controls: flumazenil pre-treatment (BZ-site specificity), naloxone (opioid receptor contribution), locomotor activity (rule out sedation confound)
- Purity standard: HPLC >99%, lot-traceable CoA; reconstitute in sterile 0.9% saline, use immediately
All compounds described are for laboratory and research use only. They are not approved for therapeutic, diagnostic, or clinical use in humans. Compliance with IACUC protocols is mandatory for all animal anxiety research.